Results 51 to 60 of about 10,368 (217)

A case of recurrent chronic eosinophilic pneumonia after switching from benralizumab to dupilumab

Respiratory Medicine Case Reports
Dupilumab inhibits interleukin-4Rα and suppresses type 2 inflammation. Careful administration of dupilumab is required because it increases the blood eosinophil count secondary to a decrease in local eosinophil counts, sometimes resulting in eosinophilic
Daiki Nakashima, Eri Mori, Nobuyoshi Otori   +2 more
doaj   +1 more source

Successful Treatment of Severe Adult Linear IgA Dermatosis Using Dupilumab

JEADV Clinical Practice, EarlyView.
ABSTRACT Linear IgA dermatosis (LAD) is a rare autoimmune subepidermal bullous dermatosis, characterised by the presence of erythematous vesiculobullous lesions arranged in rosettes or herpetiform clusters. The standard treatment involves the administration of dapsone, followed by sulfasalazine, and general corticosteroid therapy, often in combination ...
Célia Delesalle, Claire Abasq‐Thomas, Claire Bocciarelli, Amélie Bourhis, Marina Alexandre, Belen Eguia, Laurent Misery, Numa Deydier   +7 more
wiley   +1 more source

Characterizing the Epithelial Transcriptome of Type‐2 High Chronic Rhinosinusitis

International Forum of Allergy &Rhinology, EarlyView.
Brian Cameron, Jeffanie Gayoso, Christina Dorismond, Ping Li, Mason Krysinski, Rakesh Chandra, Justin Turner, Naweed Chowdhury   +7 more
wiley   +1 more source

The Role of Artificial Intelligence in Modern Allergology: A Review of Applications in Diagnosis, Prediction, and Management

JEADV Clinical Practice, EarlyView.
ABSTRACT Artificial Intelligence is rapidly transforming allergology by enhancing diagnosis, risk prediction, automation, patient communication, education, and therapy development. Machine learning approaches, including convolutional neural networks, recurrent architectures, and transformer‐based models, enable analysis of complex datasets from ...
Sebastian Seurig, Stephan Traidl, Sonja Mathes   +2 more
wiley   +1 more source

Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study

Allergology International
Background: Dupilumab is approved in Japan for the treatment of atopic dermatitis in patients aged 6 months to 18 years. However, long-term data are lacking in this patient population. Here we report the final analysis of a long-term open-label extension
Yoko Kataoka, Motohiro Ebisawa, Akio Tanaka, Mizuho Nagao, Elizabeth Laws, Hisakatsu Nawata, Kazuhiko Arima, Daisuke Watanabe, Xin Lu, Jennifer Maloney, Ariane Dubost-Brama, Ashish Bansal, Kenji Yahata   +12 more
doaj   +1 more source

Successful Co‐Administration of Secukinumab and Dupilumab in a Patient With Psoriasis and Paradoxical Atopic Dermatitis

JEADV Clinical Practice, EarlyView.
ABSTRACT Paradoxical atopic dermatitis (AD) can arise during biologic therapy for psoriasis due to an immune‐axis imbalance. We describe a 47‐year‐old man who developed severe AD while receiving secukinumab, which was successfully managed with the addition of dupilumab, allowing long‐term control of both diseases.
So Yun Park, Minjung Park, Ho Eun Gwang, Narang Hong, Hye Jung Jung, Mi Youn Park, Jiyoung Ahn   +6 more
wiley   +1 more source

The Application of Dupilumab to Pediatric Patients Aged 6–11yrs with Moderate-to-Severe Atopic Dermatitis Whose Disease is Not Adequately Controlled: The Clinical Data so Far

Drug Design, Development and Therapy, 2023
Sarah Balboul,1 Julia Kahn,1 Alexis Tracy,2 Anjelica Peacock,3 Abigail Cline2– 4 1School of Medicine, New York Medical College, Valhalla, NY, USA; 2Department of Dermatology, New York Medical College, Valhalla, NY, USA; 3Department of Dermatology ...
Balboul S, Kahn J, Tracy A, Peacock A, Cline A   +4 more
doaj  

Refractory Eczema as a Presenting Feature of Common Variable Immunodeficiency

JEADV Clinical Practice, EarlyView.
ABSTRACT Common variable immunodeficiency (CVID) is the most prevalent symptomatic inborn error of immunity (IEI) in adults. It presents with recurrent infections and non‐infectious complications, including autoimmunity, lymphoproliferation and dermatitis.
Mercedes Sanchez‐Diaz, Lars Matthies, Andrea Vanegas Ramirez   +2 more
wiley   +1 more source

Facial erythema after the treatment of dupilumab in SLE patient

Allergy, Asthma & Clinical Immunology, 2020
Background Dupilumab is a receptor antagonist binding to the alpha subunit of the interleukin-4 receptor. Through binding to it, dupilumab inhibits signaling of both IL-4 and IL-13, the representative Th2 biomarkers.
Dong Hyek Jang, Jae In Lee, Joo Yoon Bae, Hye Jung Jung, Mi Yeon Park, Jiyoung Ahn   +5 more
doaj   +1 more source

HPV‐6 Positive Eruptive Verruca Vulgaris After Upadacitinib Initiation for Severe Atopic Dermatitis

JEADV Clinical Practice, EarlyView.
ABSTRACT Oral JAK‐1 inhibitors for atopic dermatitis (AD) are associated with an increased risk of cutaneous viral infections, particularly herpes zoster. Emerging case reports further suggest a link to eruptive human papillomavirus (HPV) disease. A 23‐year‐old transgender man (female‐to‐male) with severe AD developed a rapidly disseminating eruption ...
Mohammed Shanshal, Emily Moon, Georgios Kallikas   +2 more
wiley   +1 more source